Skip to content

A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With a

Discussion Board Forums Clinical Trials A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With a

Viewing 1 post (of 1 total)
  • Author
    Posts
  • #98454
    gavin
    Moderator

    A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

    https://clinicaltrials.gov/ct2/show/NCT03684811

    Brief Summary:
    This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.

    The study is divided into two parts: single agent FT-2102 followed by combination therapy.

    Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored.

    Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102+nivolumab (hepatobiliary tumors) and FT-2102+gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.

    Gavin

Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.
©2019 - All Rights Reserved, Cholangiocarcinoma Foundation
Scroll To Top